Divozilimab
Based on 1 Customer Validation
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.63%
- CAS No.: 2254061-60-2
- Masse moléculaire:145.26 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
CD20/MS4A1
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling CD20 (red) with Divozilimab (anti-CD20) (HY-P99855). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/200 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 2254061-60-2
-
Appearance Liquid
-
Masse moléculaire 145.26 kDa
-
Color Colorless to light yellow
-
SMILES
[Divozilimab]
-
Synonyms
BCD-132
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. O V Boyko, et al. Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):87-95. [Content Brief]
[2]. Boyko AN, et al. Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(4):37-47. Russian. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Divozilimab Related Classifications
HY-P99855 Related Classifications
Powered by Bioz